Technology

Matthew Yelovich, partner at Cleary Gottlieb, discusses his transition in late-2024 from working as a federal prosecutor to a role at Cleary Gottlieb, as well as how he sees the intersection of technology and law evolving in the Bay Area.

Matthew Yelovich, partner at Cleary Gottlieb, discusses some of the broader implications for corporate governance and accountability the Theranos case highlights.

Rahman discusses Google Gemini and what it could mean to the future of pharma commercialization and content development.

If used properly, AI can be a game-changer for drug development.

Key trends in healthcare communication to build trust between healthcare providers and their patients.

Jennifer Kyle, CEO and founder of Condor, explores how improving financial management directly impacts drug pricing.

Jennifer Kyle, CEO and founder of Condor, discusses the inspiration behind creating a financial cloud platform specifically for biopharma R&D.

In an era where business-critical information is exchanged instantly, unsecured communication channels are a significant risk.

As coverage in Pharmaceutical Executive’s March issue reinforces, AI's connections and permutations are seemingly touching all parts of the industry—and only growing.

Making early commercial data and analytics decisions for launch cen future-proof their data management.

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

EVERSANA’s chief digital officer discusses recent developments in the pharma industry that are impacting its relationship with patients and new technology.

Heather Gervais, CEO of Osso VR, discusses how technological advancements in VR are solving problems for pharmaceutical sales reps.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

The CEO discusses his company’s platform that helps reformulate oral solid dose medications to liquid forms.

The benefits for brand teams in bolstering their rapid-response capability.

The TileDB CEO discusses how the life sciences can overcome these limitations.

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

Guidance marks the regulatory body’s first on artificial intelligence applications in drug and biological product development.

A Q&A with Harvard’s Laura Wegner, serial entrepreneur and Rhodes Scholar-elect.

In the third part of this roundtable discussion, experts discuss the issues with data that AI must overcome.

The Upscript Health CEO discusses trends in telehealth for the coming year.

How alternative direct-to-consumer models are changing the landscape for patient access.